There is no evidence that PUFA supplementation in infancy has an effect on infant or childhood allergy , asthma , dermatitis/eczema or food allergy .
However , the quality of evidence was very low .
There was insufficient evidence to determine an effect on allergic rhinitis
BACKGROUND Early dietary intakes may influence the development of allergic disease .
It is important to determine if dietary polyunsaturated fatty acids ( PUFAs ) given as supplements or added to infant formula prevent the development of allergy .
OBJECTIVES To determine the effect of higher PUFA intake during infancy to prevent allergic disease .
Neurodevelopmental outcomes at 7 years’ corrected age in preterm infants who were fed high-dose docosahexaenoic acid to term equivalent: a follow-up of a randomised controlled trial
Objective To determine if improvements in cognitive outcome detected at 18 months ’ corrected age ( CA ) in infants born <33 weeks ’ gestation receiving a high-docosahexaenoic acid ( DHA ) compared with st and ard-DHA diet were sustained in early childhood . Design Follow-up of a multicentre r and omised controlled trial . R and omisation was stratified for sex , birth weight ( < 1250 vs ≥1250 g ) and hospital . Setting Five Australian tertiary hospitals from 2008 to 2013 . Participants 626 of the 657 participants r and omised between 2001 and 2005 were eligible to participate .  Interventions High-DHA ( ≈1 % total fatty acids ) enteral feeds compared with st and ard-DHA ( ≈0.3 % total fatty acids ) from age 2–4 days until term CA . Primary outcome Full Scale IQ of the Wechsler Abbreviated Scale of Intelligence ( WASI ) at 7 years CA . Prespecified subgroup analyses based on the r and omisation strata ( sex , birth weight ) were conducted . Results 604 ( 92 % of the 657 originally r and omised ) consented to participate ( 291 high-DHA , 313 st and ard-DHA ) . To address missing data in the 604 consenting participants ( 22 for primary outcome ) , multiple imputation was performed . The Full Scale IQ was not significantly different between groups ( high-DHA 98.3 , SD 14.0 , st and ard-DHA 98.5 , SD 14.9 ; mean difference adjusted for sex , birthweight strata and hospital −0.3 , 95 % CI −2.9 to 2.2 ; p=0.79 ) . There were no significant differences in any secondary outcomes . In prespecified subgroup analyses , there was a significant sex by treatment interaction on measures of parent-reported executive function and behaviour . Scores were within the normal range but girls receiving the high-DHA diet scored significantly higher ( poorer outcome ) compared with girls receiving the st and ard-DHA diet . Conclusions Supplementing the diets of preterm infants with a DHA dose of approximately 1 % total fatty acids from days 2–4 until term CA showed no evidence of benefit at 7 years ’ CA . Trial registration number Australian New Zeal and Clinical Trials Registry : ACTRN12606000327583
There is no evidence that PUFA supplementation in infancy has an effect on infant or childhood allergy , asthma , dermatitis/eczema or food allergy .
However , the quality of evidence was very low .
There was insufficient evidence to determine an effect on allergic rhinitis
BACKGROUND Early dietary intakes may influence the development of allergic disease .
It is important to determine if dietary polyunsaturated fatty acids ( PUFAs ) given as supplements or added to infant formula prevent the development of allergy .
OBJECTIVES To determine the effect of higher PUFA intake during infancy to prevent allergic disease .